Condroblastomul osului: prezentare de caz, constatări imunohistochimice şi revizuirea literaturii

 Chondroblastoma of bone: case presentation, immunohistochemistry findings and literature review

First published: 28 octombrie 2020

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.52.3.2020.3712


Chondroblastoma is a rare benign cartilage-producing tu­mor, with an incidence of approximatively 1% of all pri­ma­ry bone tumors. It arises mostly in the second decade of life, affecting mainly the ends of the long tubular bones. We present two cases of chondroblastoma diagnosed and trea­ted in the “Foişor” Orthopedics, Traumatology and Oes­teo­articular TB Clinical Hospital, Bucharest, Romania. The purpose of this study is to contrast two different forms of presentation of the same histologic entity: one case of a 19-year-old male patient with a chondroblastoma lo­ca­ted in the proximal humerus, and the case of a 37-year-old male patient with a chondroblastoma of the cal­ca­neus. The mor­phological fea­tures, radiologic aspects and im­mu­no­his­tochemical stu­dies have been assessed. None of the cases presented with spe­ci­fic radiologic signs for chondroblastoma, both lesions being osteolytic and well-delineated, in favor of a benign en­ti­ty. The classic mor­pho­lo­gical aspects of chondroblastoma re­pre­sen­ted by tumor cells with round poly­gonal shape and nuclei with longitudinal grooves were as­so­cia­ted with variable amounts of chondroid matrix, pe­ri­cellular calcification and few randomly distributed osteo­clast-like giant cells. The im­mu­no­his­to­chemical studies showed the osteoblastic and chon­dro­blastic phenotype of the neoplastic cells, sustained by positivity for CD56 and S100. DOG1, cytokeratin 8/18 and smooth muscle actin (SMA) were also found focally po­si­tive. All cases were treated by curettage with bone graf­ting, without recurrence in the short-term follow-up. Given the nonspecific radiologic findings and the histologic he­te­ro­ge­nei­ty, chondroblastoma is sometimes misinterpreted as a ma­lig­nant tumor, while this neoplastic lesion has a benign be­havior and benefits from conservative surgical treatment only.

chondroblastoma, primary bone tumor, cal­ca­neus, proximal humeral epiphysis, im­mu­no­his­to­chemistry


Condroblastomul este o tumoră benignă rară, având o in­ci­den­ţă de aproximativ 1% din totalul cancerelor primare osoa­se. Se întâlneşte frecvent în a doua decadă a vieţii şi este lo­ca­li­zat în majoritatea cazurilor la nivelul epifizelor oaselor lungi. Prezentăm două cazuri de condroblastom diag­nosticate şi tratate la Spitalul Clinic de Ortopedie, Trau­ma­tologie şi TBC Osteo­articular „Foişor”, Bucureşti. Sco­pul acestui studiu este de a compara două forme di­fe­rite de prezentare ale aceleiaşi en­ti­tăţi histopatologice. Primul caz este reprezentat de un pa­cient de gen masculin, în vârstă de 19 ani, cu condroblastom la nivelul epifizei hu­me­rale proximale, iar al doilea caz este al unui pacient de gen masculin, de 37 de ani, cu condroblastom lo­ca­lizat la nivelul calcaneului. S-au evaluat aspectele ra­dio­­lo­gice şi histologice ale tumorii şi s-a analizat profilul imu­­no­histochimic al celulelor neoplazice. Investigaţiile ima­gis­ti­ce au evidenţiat leziuni osteolitice bine delimitate, fără ca­rac­te­re de specificitate, cu aspect radiologic benign. Ca­rac­te­ris­ticile histopatologice clasice ale condroblastomului sunt repre­zen­tate de celule rotunde, poligonale, cu nuclei in­dentaţi lon­gi­tu­dinal, reniformi, asociate cu o cantitate va­ria­bilă de matrice condroidă, calcificări pericelulare şi rare ce­lu­le gigante osteo­clast-like distribuite aleatoriu. Testele imu­no­his­to­chi­mice au demonstrat fenotipul osteoblastic şi condroblastic al celu­le­lor tumorale, fiind pozitive pentru CD56 şi, respectiv, S100. De ase­menea, DOG1, citokeratina 8/18, cât şi actina muşchiului ne­ted (SMA) au fost pozitive fo­cal. Ambele cazuri au fost tra­ta­te prin chiuretaj şi plombaj cu grefă osoasă, prezentând o evo­lu­ţie favorabilă, fără re­ci­di­vă postoperatorie. Ţinând cont de aspectele radiologice ne­spe­ci­fice şi de heterogenitatea tră­să­tu­rilor histopatologice, con­dro­blas­to­mul poate fi perceput une­ori ca o tumoră ma­lig­nă, deşi această entitate are un com­por­ta­ment benign şi se tra­tea­ză exclusiv chirurgical. 


Chondroblastoma is a rare benign cartilage-producing tumor, its incidence accounting for less than 1% of all primary bone tumors(1). Formerly known as “calcifying giant cell tumor” or “epiphyseal chondromatous giant cell tumor”, in 1942 the name of benign chondroblastoma of bone was introduced for the first time, describing its distinctive clinicopathologic features(2-3).

It arises mostly in the second decade of life, being more prevalent in men, and affects mainly the ends of the long tubular bones of the skeletally immature individuals. The common sites of involvement include the epiphysis of proximal humerus, proximal and distal femur and proximal tibia(3-6). In older individuals, the location varies more and may include non-tubular bones, craniofacial bones, bones of hands and feet(7). This entity has also been described in flat bones such as clavicle, sternum, ribs, vertebrae, pelvis and patella(5).

It is usually a solitary lesion, which involves the medullary cavity of the long bones(3). In flat bones, the tumor may extend into apophysis and into the articular space. Even though epiphysis of long tubular bones represents the common site of presentation, there are cases reported to arise in non-epiphyseal locations(8).

The most common clinical symptom is pain, which can be accompanied by other changes, such as swelling, stiffness, effusion and limitation in range of motion(6).

On plain radiographs, chondroblastoma appears as a well-circumscribed, eccentric, radiolucent lesion with a thin sclerotic rim(9). The computed tomography can reveal areas of mineralization. Calcifications appear as radiodensities and their amount varies greatly. When present in the chondroid matrix, they are described as arcs and rings of calcification(10). Adjacent cortex may be eroded or thinned, but rarely disrupted. In those cases associated with pathological fracture, a periosteal reac­tion may be seen. Lesions that do not arise in the epi­phy­sis have nonspecific imaging findings(3).

The differential diagnosis based on radiologic ima­ging includes giant cell tumor of bone, enchondroma, chon­dro­myxo­id fibroma, low-grade chondrosarcoma, low-grade intramedullary osteosarcoma, and clear cell chon­dro­sar­coma(11).

The peritumoral inflammatory reaction (especially edema) may be assessed through MRI studies(9). The intensity of T1- and T2-weighted MRI images depends on the amounts of various components within the lesion, such as cartilaginous component, cellularity, calcification, hemorrhage and cystic areas(9).

Tissue is often obtained from curettage and comes in many fragments, giving the impression of a lobular ar­chi­tec­ture. It presents as a grey yellow, friable ma­te­rial, usually with gritty cut surface calcifications. The chondroid component appears as a rubbery blue gray material, sometimes with bone consistency. The frag­ments may be hemorrhagic(3).

Histologically, this tumor is characterized by a pro­li­fe­ration of chondroblasts, chondroid matrix, cal­ci­fi­ca­tions, various amounts of giant cells, and is occasionally as­so­cia­ted with aneurysmal bone cyst (ABC). Tumoral cells have a round polygonal shape, with well-defined cyto­plas­mic borders. The cytoplasm may be eosinophilic or focally clear. The nuclei have a characteristic appearance, with a central longitudinal groove (“cof­fee bean nucleus”)(3,12). The benign osteoclast-like giant cells of small di­men­sions are randomly dis­tri­bu­ted through the tumor, but their presence is not mandatory. Few mitoses may be visible, with a mitotic count of 1-3 mitoses/10 HPF. The presence of atypical mitoses excludes the diagnosis of chondroblastoma. Pericellular lace-like calcifications with “chicken-wire” appearance strongly support the diagnosis(3,11). Foci of hemosiderin deposition may be seen in the cytoplasm of the neoplastic cells. Half of the tumors of the hand and feet develop secondary ABC.

Some tumors may be locally aggressive, with cortical breakthrough and soft tissue invasion(11). Tumor necrosis and new bone formation can be seen when pathologic fracture is associated(11).

The immunohistochemical stains demonstrated that tumor cells are CD56, S100, CAM5.2 and vimentin positive. Focal positivity for keratins 8/18 and 19 was also described(13). An interesting relatively sensitive and specific marker for chondroblastoma is DOG1, which is known to be highly specific for gastrointestinal stromal tumors(14). SOX9 is positive in both chondroblastoma and chondromyxoid fibroma. Positive staining for Galectin-1 is considered reactive and is nonspecific, as it may be positive in 50% of chondroblastic osteosarcomas(10).

Recent studies identified a K36M mutation in H3 histone family member 3A (H3F3A) or 3B (H3F3B) genes, which proved a high sensitivity and specificity for chondroblastoma. Immunohistochemistry using antibodies against H3K36M is already available in some centers(15-18).

Depending on the histopathologic aspects, the dif­fe­ren­tial diagnosis may include giant cell tu­mor of bone, chon­dro­myxoid fibroma, secondary aneu­rys­mal bone cyst, clear cell chondrosarcoma, and chon­dro­blas­to­ma-like variant of osteosarcoma(11).

The treatment of choice is the complete surgical cu­ret­­tage with or without bone grafting. As in giant cell tu­mor of bone (GCT), the chemical cauterization with phe­nol and cryotherapy may be used during the sur­gi­cal pro­ce­dure. En bloc resection may be necessary if ag­gres­sive recurrences occur and they cannot be treated by curet­tage(3-5). Amputation is an exceptional event.

Radiotherapy, previously used, is not yet recom­men­ded, as it leads to postradiation malignancy(3). It can be used when complete resection is not possible. Che­mo­the­rapy is not indicated(10).

The term “aggressive chondroblastoma”, which has no established relationship with the histologic appearance, was attributed to those exceptionally rare cases with lung metastases – more properly named lung implants – as they do not have the same unfavorable outcome as a malignant tumor(1,10).

Case presentation

We present two cases of chondroblastoma diagnosed and treated in the “Foişor” Orthopedics, Traumatology and Oesteoarticular TB Clinical Hospital, Bucharest, Romania. The patients were admitted for pain and movement limitation. Clinical and imagistic records, as well as treatment and postoperative evolution were gathered from the hospital record system. In our laboratory, we assessed histopathological diagnosis and im­mu­no­his­to­chemistry (IHC) studies. Solid tumors diameters were measured using computed tomography.

Tumor tissue was fixed in 10% neutral buffered for­malin and embedded in paraffin. The histologic sections were cut at 3 micrometers thickness. The standard stain was hematoxylin and eosin. Immunohistochemistry was carried out using LEICA BOND III automatic ma­chine with Leica Bond antibodies for: CD 56 (clone 564), S100 polyclonal, SMA (clone osm1), CK8/18 (clone 5D3), and Ki-67 (clone MM1). DOG1 stain (Biocare mouse monoclonal antibody) was performed manually.

The histologic features evaluated included: giant cells, pattern of calcification, bone metaplasia, mitoses, chondroid material, cytologic atypia, necrosis, mature hyaline cartilage formation, and the presence of ABC.

Case 1

A 19-year-old male patient was admitted in our hospital for short-term persistent pain (two months) localized in the left shoulder. The imaging investigations revealed a well-de­li­neated expansile tumoral lesion in­vol­ving proximal left hu­meral epiphysis (Figure 1). The bone lesion measured 58.5/46/50 mm, was hete­ro­genous, osteolytic, with in­creased peripheral bone den­sity. As imaging findings fa­vored a benign process, but associated with a rather broad dif­fe­ren­tial diagnosis, a bone biopsy was performed. 

The histopathology revealed a proliferation of po­ly­­gonal tumoral cells, with eosinophilic cytoplasm and round cen­tral vesicular nuclei, some of which had lon­gi­tu­di­nal nu­clear grooves (“coffee bean-like nu­clei”). The sheet-like proliferation of tumoral cells was associated with chon­droid matrix formation, bone me­ta­plasia and focal cal­ci­fi­ca­tions of chondroid matrix (Figure 2). Pericellular cal­ci­fi­ca­tions with “chicken wire” configuration and tumor cells containing hemosiderin pigment were focally seen. Only a small number of osteo­clast-like giant cells were pre­sent. Obvious cytologic atypia was absent.

After the diagnosis of chondroblastoma was rendered, the surgical treatment was decided. The patient under­went curettage and grafting with allograft bone. The postoperative course was uneventful. 

Figure 1. Imaging findings of chon­dro­blas­toma in a 19-year-old patient.
Figure 1. Imaging findings of chon­dro­blas­toma in a 19-year-old patient.
Figure 2. Histologic aspects of chondroblastoma.
Figure 2. Histologic aspects of chondroblastoma.

Case 2

A 37-year-old male patient was admitted in our hospital for pain in the left foot. Conventional radiographs showed a well demarcated lytic lesion with a sclerotic rim, suspicious of a cystic benign lesion, situated in the subthalamic region of the calcaneus (Figure 3). Frozen section diagnosis of chondroblastoma was rendered (Figure 4B). The patient underwent de­fi­ni­tive surgery in one step, with curettage and bone graf­ting with allograft bone. 

The tissue obtained from curettage came in several frag­ments of cartilaginous consistency, with spotty calci­fi­cations, altogether not measuring more than 2/1 cm (Figure 4A). The microscopic features revealed sheets of polygonal cells with well-defined cell borders and nuclei with characteristic longitudinal grooves. These aspects were associated with islands of calcified chondroid matrix. “Chicken wire” pericellular calcifications were focally noticed. Rare osteoclast-like giant cells were randomly distributed. The mitotic activity was low, with no atypical figures. Hemorrhagic areas with hemosiderin deposition were also present (Figure 4C).

Both tumors were positive for CD56, DOG1, S100, CK 8/18, SMA and vimentin (Figure 5). In both cases, the Ki-67 proliferation index was very low: 1-3% of tumor cells.

Figure 3. A) Conventional radiograph of a chon­dro­blas­toma shows a well-de­mar­cated lytic le­sion with a sclerotic rim si­tua­ted in the subthalamic re­gion of the calcaneus; B) Ra­dio­gra­phic findings after sur­gi­cal treatment
Figure 3. A) Conventional radiograph of a chon­dro­blas­toma shows a well-de­mar­cated lytic le­sion with a sclerotic rim si­tua­ted in the subthalamic re­gion of the calcaneus; B) Ra­dio­gra­phic findings after sur­gi­cal treatment
Figure 4. Chondroblastoma in a 37-year-old patient.
Figure 4. Chondroblastoma in a 37-year-old patient.
Figure 5. IHC positive stains in chondroblastoma
Figure 5. IHC positive stains in chondroblastoma


Chondroblastoma is a rare tumor of bone which can be easily diagnosed when classic morphological findings match the imaging data. Even though the radiological aspects may favor a benign diagnosis, several other entities could be envisaged in the differential diagnosis, among which some low-grade malignancies such as well-differentiated chondrosarcoma, low-grade intramedullary osteosarcoma, and giant cell tumor of bone.

The first case fits all the criteria described in lite­ra­ture, including the patient’s age and sex, the typical tu­mor location and the histopathological aspects. Even though conventional radiographs showed an osteolytic well-demarcated lesion in the humeral epiphysis, in fa­vor of a benign process, malignancy could not be ex­clu­ded on imaging findings. One particular feature was represented by bone metaplasia, which can mimic other tumoral entities, such as osteosarcoma, and the diag­no­sis may become really difficult on small biopsy material. 

In the second case, the diagnosis of chondroblastoma was not anticipated, due to unusual clinical and topo­gra­phic presentation, with radiological features consistent of a bone cyst. Chondroblastoma arising in adults tends to affect the short bones of the hand and feet, rather than the epiphysis of the long bones(19). Even though it was demonstrated that the histological aspects of this tumor in adults are prone to present with more calcifications, necrosis and other degenerative changes(19), we did not find necrosis in our specimen. Nevertheless, the histological features respected all the necessary criteria for the diagnosis of chondroblastoma, which was rendered on frozen sections and confirmed on paraffin.

Neoplastic cells with intracytoplasmic hemosiderin deposits were found in both of our tumors, this feature being more common among chondroblastoma of the craniofacial bones(3,10,11).

The histologic aspects that should raise concern are atypical mitoses, islands of mature cartilage in the tumor tissue, extensive necrosis and vascular, bone or soft tissue invasion. Neoplastic cells of chondroblastoma usually have a low number of mitoses, but only the presence of atypical mitoses should question the diagnosis of chondroblastoma(11). Our cases had a low mitotic index expressed through the proliferation index Ki-67 of 1-3% of the neoplastic cells.

If mature cartilage is present in the neoplastic lesion, the diagnosis of chondroblastoma should be carefully revised(10). This change may be apparent when a pathologic fracture is associated but, otherwise, an osteosarcoma or a chondrosarcoma should be taken into consideration. As a consequence, biopsy should not be taken from the fracture site, as this may lead to an erroneous diagnosis. Neither of these changes has been present in our cases.

As pulmonary implants have been described in several cases(1), our patients were also investigated with thoracic imaging, and neither of them had lung lesions. Soft tissue invasion and intraarticular extension may be seen in locally aggressive chondroblastoma or in long standing, neglected lesion, leading to radical surgery(12).

Depending on the various histopathologic aspects that can occur in a chondroblastoma, the differential diagnosis may include giant cell tumor of bone, chondromyxoid fibroma, secondary aneurysmal bone cyst, clear cell chondrosarcoma, and chondroblastoma-like variant of osteosarcoma.

  • Giant cell tumor (GCT) of bone usually occurs in skeletally mature bones. The lack of nuclear grooves in mononuclear cells, chondroid matrix and “chicken wire” calcifications are against the diagnosis of GCT. More­over, giant cells tend to be evenly distributed among the tumor. The mononuclear cells are negative for S100, keratins and DOG1, and usually positive for p63(10).

  • Chondromyxoid fibroma may extend sometimes into the epiphyses, but lacks “chicken wire” calcifications and nuclear grooves, although both lesions can contain numerous osteoclast-like giant cells. It is characterized by centrally located hypocellular chondromyxoid matrix surrounded by hypercellularity. Immunohistochemistry shows a positivity for S100, but is negative for cyto­keratins and DOG1(3,10).

  • ABC (especially solid type). It is preferable to do extensive sampling in order to identify tumoral tissue, when found centered in the epiphysis, because ABC can be a predominant finding and can overshadow an underlying chondroblastoma or other entity(10).

  • Clear cell chondrosarcoma should have invasive features and should contain cartilaginous matrix, which is absent in chondroblastoma(11).

  • Chondroblastoma-like variant of osteosarcoma presents an aggressive radiographic appearance, with tumor cells with greater degree of atypia than those found in chondroblastoma, and neoplastic osteoid(1,10,11).

Immunohistochemical studies are not always man­da­tory, but some markers still remain of interest in the controversial histogenesis of the tumor. DOG1 positivity is an unexplained finding in this type of tumor, this marker being highly expressed in gastrointestinal stro­mal tumor. DOG1 is also useful in the differential diag­nosis with other giant cell rich tumors, its presence con­fir­ming the diagnosis of chondroblastoma(14). Cyto­ke­ratin positivity (CK8/18) is focally seen(10,14).

The intensity of the immunohistochemical stains varied depending on the markers used. The strongest expression was seen with CD56 (which is known as a surrogate for osteoblastic differentiation) and S100 (also strongly expressed in cartilaginous tumors), which was consistent with the dual accepted phenotype of the neoplastic cell, osteoblastic and chondroblastic (Figures 5A and 5B).

This polymorphic expression of immu­no­his­to­che­mis­try markers highlights the unclear pathogenesis of this tumor. As chondroblastoma expresses genes in­volved in cartilage formation together with chon­dro­my­xoid fibroma, but also shares loss of heterozygosity pat­tern with low-grade chondrosarcoma, this tumor remains in the family of cartilaginous neo­plasms(20,21). Transmission electron microscopy and immunoperoxidase studies also supported the cartilaginous origin of this tumor(3).

Recent studies identified a K36M mutation in H3 histone family member 3A (H3F3A) or 3B (H3F3B) genes, which proved a high sensitivity and specificity for chondroblastoma. A mutation in the H3F3B gene is more frequent. This mutation was not found in other histologic mimics such as GCT, GCT of Paget disease, ABC solid variant and osteosarcoma(18). Despite the fact that another mutation (G34W) in H3F3A gene was found in GCT of bone, this alteration was not present in chondroblastoma(15-18). Immunohistochemistry for K36M mutation is already available in some centers but, unfortunately, it is not available yet in our center, so we do not have any experience with it. We consider that its use may be beneficial in the differential diagnosis of giant cell-rich tumors and in confirming the morphological diagnosis of chondroblastoma.

The treatment of choice is curettage with bone graf­ting, and usually no further treatment is necessary. The recurrence rate in chondroblastoma was described to be around 14-18%(1), and was associated with tumor location or incomplete curettage(3,22). Some authors have reported an increased risk of recurrence in patients with chondroblastoma of flat bones or in those lesions associated with secondary ABC(3,23).

Both of our tumors were treated by curettage with bone grafting. One-step surgery, as done in the second case, is recommended when imaging data strongly favor a benign lesion. The diagnosis of chondroblastoma is confirmed by frozen section, thus reducing the patient’s stress regarding surgical procedures such as bone biopsy.


Osteoblastic and chondroblastic phenotype of the neoplastic cells in chondroblastoma is highlighted by the positivity for CD56 and S100, respectively. The polymorphic expression of IHC markers emphasizes the unclear histogenesis of the tumor.

Considering the radiologic findings and the his­to­logic heterogeneity, chondroblastoma is sometimes misinterpreted as a malignant tumor. Its proper diag­no­sis is of outmost importance as this tumor has a be­nign behavior and benefits from conservative surgical treat­ment only.


  1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013; 24.

  2. Jaffe HL, Lichtenstein L. Benign chondroblastoma of bone: a reinterpretation of the so-called calcifying or chondromatous giant cell tumor. Am J Pathol. 1942; 18:969-991. 

  3. Unni KK, Inwards CY. Dahlin’s Bone Tumors. 6th ed. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business. 2010.

  4. Edel G, Ueda Y, Nakanishi J, et al. Chondroblastoma of bone: a clinical, radiological, light and immunohistochemical study. Virchows Arch A Pathol Anat. 1992; 421(4):355–366.  

  5. Kurt A-M, Unni KK, Sim FH, McLeod RA. Chondroblastoma of bone. Hum Pathol. 1989; 20(10):965–976.  

  6.  Turcotte RE, Kurt A-M, Sim FH, Unni KK, McLeod RA. Chondroblastoma. Hum Pathol. 1993; 24(9):944–949. 

  7. John I, Inwards CY, Wenger DE, Williams DD, Fritchie KJ. Chondroblastomas presenting in adulthood: a study of 39 patients with emphasis on histological features and skeletal distribution. Histopathology. 2020; 76:308-317. 

  8.  Brien EW, Mirra JM, Ippolito V. Chondroblastoma arising from a nonepiphyseal site. Skeletal Radiol. 1995; 24(3):220–222. 

  9. Shinmura K, Ishida T, Goto T, et al. Expression of cyclooxygenase-2 in chondroblastoma: immunohistochemical analysis with special emphasis on local inflammatory reaction. Virchows Arch. 2004; 444, 28–35. 

  10. Bocklage TJ, Quinn RH, Schmit BP, Verschraegen CF. Bone and soft tissue tumors. A multidisciplinary review with case presentations. London: JP Medical Ltd., 2014.

  11. Nielsen GP, Rosenberg AE, Deshpande V, Hornicek FJ, Kattapuran SV, Rosenthal DI. Diagnostic Pathology: Bone, 2nd ed. Philadelphia: Elsevier, 2017.

  12. de Silva MVC, Reid R. Chondroblastoma: varied histological appearance, potential diagnostic pitfalls, and clinicopathologic features associated with local recurrence. Ann Diagn Pathol. 2003; 7(4):205–213. 

  13. Bousdras K, O’Donnell P, Vujovic S, Henderson S, Boshoff C, Flanagan AM. Chondroblastomas but not chondromyxoid fibromas express cytokeratins: an unusual presentation of a chondroblastoma in the metaphyseal cortex of the tibia. Histopathology. 2007; 51: 414-416. 

  14. Akpalo H, Lange C, Zustin J. Discovered on gastrointestinal stromal tumour 1 (DOG1): useful immunohistochemical marker for diagnosing chondroblastoma. Histopathology. 2012; 60(7):1099–1106. 

  15. Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45(12):1479–1482. 

  16. Amary F, Berisha F, Ye H, et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017; 41:1059-1068. 

  17. Amary MF, Berisha F, Mozela R, et al. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology. 2016; 69:121-127. 

  18. Schaefer IM, Fletcher JA, Nielsen GP, Shih AR, Ferrone ML, Hornick JL, Qian X. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. 2018 Aug; 126(8):552-566. 

  19. Negri S, et al. Clinicopathologic Analysis of Chondroblastoma in Adults: A Single-Institution Case Series. International Journal of Surgical Pathology. June 2020;

  20. Romeo S, Oosting J, Rozeman LB, et al. The role of noncartilage-specific molecules in differentiation of cartilaginous tumors. Lessons from chondroblastoma and chondromyxoid fibroma. Cancer. 2007; 110:385–94. 

  21. Papachristou DJ, Goodman MA, Cieply K, Hunt JL, Rao UN. Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization analysis. Hum Pathol. 2006; 37(7):890-898.

  22. Springfield DS, Capanna R, Gherlinzoni F, Picci P, Campanacci M. Chondro­blas­to­ma: a review of seventy cases. J Bone Joint Surg. 1985; 67:748-54.

  23. Ramappa AJ, Lee FY, Tang P, Carlson JR, Gebhardt MC, Mankin HJ. Chon­dro­blas­to­ma of bone. J Bone Joint Surg Am. 2000; 82(8):1140-1145.

Articole din ediţiile anterioare

SHORT REVIEWS | Ediţia 2 55 / 2021

Review al carcinomului cu celule Merkel – ce se ştie şi ce nu se ştie?

Conf. dr. Dana Lucia Stănculeanu, Adelina Silvana Dragomir, Liliana-Cristina Popescu, Elena Adriana Mateianu, Isabela Anda Komporaly, Andreea Mihaela Radu, Daniela Zob, Raluca Ioana Mihăilă

Carcinomul cu celule Merkel (MCC) este o formă rară de can­cer cutanat – carcinom neuroendocrin – şi se găseşte frec­vent în regiunile corpului exp...

24 aprilie 2021
HISTOPATOLOGIE | Ediţia 2 / 2015

Importanţa examenului imunohistochimic în stabilirea prognosticului cancerului pulmonar fără celule mici

Antonela Dragomir, Prof. dr. Florin Mihălţan, Florina Vasilescu, Ruxandra Ulmeanu

Cancerul pulmonar este prima cauză de deces prin cancer la nivel european şi mondial. Aproximativ 80% din cancerele pulmonare sunt reprezentate de ...

24 aprilie 2015
ORIGINAL RESEARCH | Ediţia 1 58 / 2022

Preliminary results of markers as predictors for the tissue response to radiochemotherapy in rectal cancer

Sânziana Ionescu, Petre Radu, Octavia Luciana Madge, Victor Strâmbu

Radiochimioterapia preoperatorie (p-CRT) este o tehnică utilizată pe scară largă pentru tratarea cancerului rectal local avansat, a cancerului esof...

25 martie 2022